Doximity, Inc. (DOCS)
| Market Cap | 5.84B -53.3% |
| Revenue (ttm) | 655.57M +11.2% |
| Net Income | 167.05M -29.0% |
| EPS | 0.84 -27.9% |
| Shares Out | 178.25M |
| PE Ratio | 38.88 |
| Forward PE | 22.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,202,269 |
| Open | 33.48 |
| Previous Close | 33.63 |
| Day's Range | 32.49 - 33.89 |
| 52-Week Range | 17.15 - 67.10 |
| Beta | 1.29 |
| Analysts | Hold |
| Price Target | 31.11 (-5.04%) |
| Earnings Date | Nov 5, 2026 |
About DOCS
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools... [Read more]
Financial Performance
In fiscal year 2026, Doximity's revenue was $644.86 million, an increase of 13.05% compared to the previous year's $570.40 million. Earnings were $196.05 million, a decrease of -12.16%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for DOCS stock is "Hold." The 12-month stock price target is $31.11, which is a decrease of -5.04% from the latest price.
News
Doximity launches DoseCheck, an additional safety layer in Doximity Ask
Doximity (DOCS) has launched DoseCheck, a free additional safety layer in Doximity Ask that instantly checks every AI-generated medication dosing claim against a structured drug database to reduce tre...
Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors Before They Reach Doctors
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, has launched DoseCheck, a free additional safety layer in Doximity Ask that in...
What Does Doximity, Inc.'s 23% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges Doximity, Inc. failed to disclose key facts to investors from August 8, 2024 through May 13, 2026; lead plaintiff deadline is November 16, 2026 BENSALEM TOWNSHIP, Pa., Oct. 28, 2026 /PRNe...
What Should Doximity, Inc. Investors Know After 23% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges Doximity, Inc. made misleading statements to investors from August 8, 2024 to May 13, 2026; lead plaintiff motions are due November 16, 2026 LOS ANGELES, Oct. 27, 2026 /PRNewswire/ -- ...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Doximity, Inc. Lawsuit - DOCS
Doximity reported "record engagement" using metrics of its own design, yet the securities action contends its disclosures omitted the market share erosion and light-engagement advertising methods that...
Kaplan Fox Alerts Doximity, Inc. (DOCS) Investors to an Approaching Lead Plaintiff Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: D...
Kaplan Fox Reminds Doximity, Inc. (DOCS) Investors to Seek a Leadership Role Before Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: D...
Doximity, Wolters Kluwer partner to bring UpToDate to Doximity Ask
Doximity (DOCS) and Wolters Kluwer Health (WTKWY) announced that UpToDate’s trusted, evidence-based, clinical content will be accessible directly within Doximity’s fast-growing AI clinical decision su...
Doximity and Wolters Kluwer Sign Partnership to Bring UpToDate to Doximity Ask
SAN FRANCISCO & WALTHAM, Mass.--(BUSINESS WIRE)--Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, and Wolters Kluwer Health, today announced that UpToDate's trusted,...
Doximity price target raised to $23 from $20 at BofA
BofA raised the firm’s price target on Doximity (DOCS) to $23 from $20 and keeps an Underperform rating on the shares. The firm’s quarterly survey on pharma advertising was “surprisingly…
Kaplan Fox Notifies Investors of Doximity, Inc. (DOCS) of the Lead Plaintiff Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: D...
Kaplan Fox Urges Doximity, Inc. (DOCS) Investors to Contact the Firm Before the Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: D...
Doximity to Release Fiscal 2027 Second Quarter Results on November 5, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ...
DOCS Stockholders Have Rights - If you Lost Money Investing in Doximity, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired D...
Doximity extends 13-year partnership with U.S. News & World Report
Doximity (DOCS) announced it has extended its 13-year partnership with U.S. News & World Report.
Doximity and U.S. News & World Report Extend Partnership to Connect Patients with Hospitals and Doctors
SAN FRANCISCO & WASHINGTON--(BUSINESS WIRE)--Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced it has extended its 13-year partnership with U.S. News ...
Kaplan Fox Encourages Doximity, Inc. (DOCS) Investors to Contact the Firm Before the Deadline on November 16, 2026 for a Leadership Role
New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DO...
Kaplan Fox Advises Doximity, Inc. (DOCS) Investors to Act Before the Lead Plaintiff Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DO...
Doximity price target lowered to $35 from $40 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Doximity (DOCS) to $35 from $40 and keeps an In Line rating on the shares.
Robbins LLP is Investigating Allegations that Doximity, Inc. Failed to Disclose to Investors it Was Losing Market Share to its Competitors With More Favorable Pricing and Engagement Models
San Diego, California--(Newsfile Corp. - September 28, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased o...
Kaplan Fox Reminds Doximity, Inc. (DOCS) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE:...
Doximity Named Leading Clinical AI Benchmark in Fireworks' Cross-Industry Index
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has been named a founding partner in the launch of a n...
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Doximity, Inc. (DOCS)
Philadelphia, Pennsylvania--(Newsfile Corp. - September 18, 2026) - Grabar Law Office is investigating potential claims on behalf of long-term shareholders of Doximity, Inc. (NYSE: DOCS) concerning wh...
DOXIMITY, INC. (DOCS) INVESTOR ALERT Investors With Large Losses in Doximity, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acqui...
Doximity downgraded to Hold from Buy at Freedom Capital
Freedom Capital downgraded Doximity (DOCS) to Hold from Buy with a price target of $27, up from $24. the company cut its fiscal 2027 EBITDA outlook to reflect another step-up…